1Bruce A. Strategies to prevent the metabolic syndrome at the population level: role of authorities and non-governmental bodies. Br J Nutr,2000,83 (Suppl) 1:S181
2Weiner DE, Sarnak MJ. Microaibuminuria: a marker of cardiovascular risk. Am J Kidney Dis,2003,42(3) :596
3Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med, 2003,139(11): 901
4Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. Am J Hypertens,2001,14(6 Pt 2): 103S
5Dwyer TM, Bigler SA, Moore NA, et al. The altered structure of renal papillary outflow tracts in obesity. Ultrastruct Pathol, 2000,24(4): 251
6Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension, 2003,41(5): 1063
7Palaniappan L, Carnethon M, Fortmann SP, et al. Association between microalbuminuria and the metabolic syndrome: NHANES Ⅲ . Am J Hypertens, 2003,16(11 Pt 1): 952
8Rowley KG, Iser DM, Best JD, et al. Albuminuria in Australian Aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia,2000,43( 11 ): 1397
9Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med, 2004,140(3):167
10Jeffrey R, Henegar SA, Bigler LK. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol, 2001,12:1211
